» Articles » PMID: 35256957

Structurally Defined Tandem-responsive Nanoassemblies Composed of Dipeptide-based Photosensitive Derivatives and Hypoxia-activated Camptothecin Prodrugs Against Primary and Metastatic Breast Tumors

Overview
Publisher Elsevier
Specialty Pharmacology
Date 2022 Mar 8
PMID 35256957
Authors
Affiliations
Soon will be listed here.
Abstract

Substantial progress in the use of chemo-photodynamic nano-drug delivery systems (nano-DDS) for the treatment of the malignant breast cancer has been achieved. The inability to customize precise nanostructures, however, has limited the therapeutic efficacy of the prepared nano-DDS to date. Here, we report a structurally defined tandem-responsive chemo-photosensitive co-nanoassembly to eliminate primary breast tumor and prevent lung metastasis. This both-in-one co-nanoassembly is prepared by assembling a biocompatible photosensitive derivative (pheophorbide-diphenylalanine peptide, PPA-DA) with a hypoxia-activated camptothecin (CPT) prodrug [(4-nitrophenyl) formate camptothecin, N-CPT]. According to computational simulations, the co-assembly nanostructure is not the classical core-shell type, but consists of many small microphase regions. Upon exposure to a 660 nm laser, PPA-DA induce high levels of ROS production to effectively achieve the apoptosis of normoxic cancer cells. Subsequently, the hypoxia-activated N-CPT and CPT spatially penetrate deep into the hypoxic region of the tumor and suppress hypoxia-induced tumor metastasis. Benefiting from the rational design of the chemo-photodynamic both-in-one nano-DDS, these nanomedicines exhibit a promising potential in the inhibition of difficult-to-treat breast tumor metastasis in patients with breast cancer.

Citing Articles

Potential of epithelial membrane protein 3 as a novel therapeutic target for human breast cancer.

Wang Y, Tuan Y, Wang J, Chang H, Chu C, Chen Y Oncol Rep. 2024; 53(1).

PMID: 39611484 PMC: 11632653. DOI: 10.3892/or.2024.8849.


Stimuli-activatable nanomedicine meets cancer theranostics.

Li H, Feng Y, Luo Q, Li Z, Li X, Gan H Theranostics. 2023; 13(15):5386-5417.

PMID: 37908735 PMC: 10614691. DOI: 10.7150/thno.87854.


New opportunities and challenges of natural products research: When target identification meets single-cell multiomics.

Zhu Y, Ouyang Z, Du H, Wang M, Wang J, Sun H Acta Pharm Sin B. 2022; 12(11):4011-4039.

PMID: 36386472 PMC: 9643300. DOI: 10.1016/j.apsb.2022.08.022.


Carrier-free supramolecular nanoassemblies of pure LSD1 inhibitor for effective anti-tumor therapy.

Li B, Zhang X, Li J Front Chem. 2022; 10:1012882.

PMID: 36247676 PMC: 9561089. DOI: 10.3389/fchem.2022.1012882.

References
1.
Cui D, Huang J, Zhen X, Li J, Jiang Y, Pu K . A Semiconducting Polymer Nano-prodrug for Hypoxia-Activated Photodynamic Cancer Therapy. Angew Chem Int Ed Engl. 2019; 58(18):5920-5924. DOI: 10.1002/anie.201814730. View

2.
Hansson L, Friedler A, Freund S, Rudiger S, Fersht A . Two sequence motifs from HIF-1alpha bind to the DNA-binding site of p53. Proc Natl Acad Sci U S A. 2002; 99(16):10305-9. PMC: 124909. DOI: 10.1073/pnas.122347199. View

3.
Chen D, Li M, Luo J, Gu W . Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. J Biol Chem. 2003; 278(16):13595-8. DOI: 10.1074/jbc.C200694200. View

4.
Sun B, Luo C, Yu H, Zhang X, Chen Q, Yang W . Disulfide Bond-Driven Oxidation- and Reduction-Responsive Prodrug Nanoassemblies for Cancer Therapy. Nano Lett. 2018; 18(6):3643-3650. DOI: 10.1021/acs.nanolett.8b00737. View

5.
Sanchez-Puig N, Veprintsev D, Fersht A . Binding of natively unfolded HIF-1alpha ODD domain to p53. Mol Cell. 2005; 17(1):11-21. DOI: 10.1016/j.molcel.2004.11.019. View